DiNAQOR, a genetic medicine platform business focused on severe hereditary heart disorders, today announced the appointment of seasoned medical device expert Mark Dehdashtian as Executive Vice President, Medical Devices.Mr. Dehdashtian will supervise DiNAQOR newly created medical device segment, including its new production site in Laguna Hills, Calif., as the firm expands its U.S. footprint. He will be in charge of developing genetic medicine delivery devices for the Company’s multi-organ access catheter platform.
“Mark brings to DiNAQOR the experience gained over 30 years of creating and bringing to market groundbreaking medical devices that improve patient’s lives,” said Johannes Holzmeister, M.D., Chairman and CEO of DiNAQOR. “We are pleased to have a true industry leader take on this critical job, especially at such an exciting moment for our organization.”
“My career has been committed to creating and introducing game-changing technology to patients,” Mr. Dehdashtian explained. “DiNAQOR organ access platform is a true advance in the administration of genetic medications, particularly gene therapies, which can improve patient care. I’m delighted to be a part of this and to assist expands its footprint in the United States. catheter-based, targeted organ access technology allows gene treatments to be delivered directly to the heart muscle, increasing biodistribution and transduction of cardiac cells.